Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05461820
Other study ID # 2016-SR-037
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date May 1, 2018
Est. completion date July 31, 2030

Study information

Verified date December 2023
Source The First Affiliated Hospital with Nanjing Medical University
Contact Xuqin Zheng
Phone 13912902902
Email zhengxuqin@njmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, the dose of methimazole was adjusted according to the different states of thyroid function, and the effects of conventional therapy and intensive therapy on the cumulative recurrence of Graves' hyperthyroidism after two years of drug withdrawal were evaluated. At the same time, the changes of immune indexes and inflammatory factors in the regulation process were evaluated. This study is a phase IV clinical study designed and carried out by the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), which is a randomized, open and routine treatment group with parallel control.


Description:

The results show that the high recurrence rate of antithyroid drugs may be related to the insufficient treatment time, the fact that thyroid autoantibodies did not turn negative when the drugs were stopped, and the thyroid volume did not shrink after treatment. However, individual differences are large, and there is no clear conclusion yet. Graves hyperthyroidism is a common organ-specific autoimmune disease, and its diagnosis mainly depends on the detection of thyroid autoantibodies, especially thyroid-stimulating receptor (TRAb). The antigens in thyroid gland include thyroglobulin (Tg), thyroid peroxidase (TPO) and sodium iodide symporter (NIS) besides thyroid stimulating receptor (TR). Graves hyperthyroidism patients were not only positive for TRAb, but also some patients were positive for anti-thyroglobulin antibody (TgAb) and anti-thyroid peroxidase antibody (TPOAb). At present, the traditional antithyroid drug treatment scheme is to adjust the dosage according to whether the thyroid function returns to normal or not, and observe the antibody turning negative at the same time, and only pay attention to whether TRAb turns negative or not. It has been found that whether TPOAb turns negative when stopping the drug can predict the recurrence after stopping the drug, suggesting that it is not only necessary to observe whether TRAb turns negative, but also to pay attention to whether other thyroid autoantibodies turn negative during the treatment of hyperthyroidism. The negative conversion of all antibodies may indicate that autoantigens are no longer exposed, and the immune balance is stable. Methimazole (MMI) is one of the most important antithyroid drugs in the treatment of Graves' disease. It mainly blocks the synthesis of thyroid hormone by inhibiting the activity of peroxidase and reduces the production of thyroid hormone. At the same time, some studies have found that methimazole has immunomodulatory effect. Methimazole is recommended for initial treatment of first-time Graves' hyperthyroidism. 30mg/d is suitable for severe Graves' hyperthyroidism and 15mg/d is suitable for mild and moderate Graves' hyperthyroidism. Research has used blocking alternative methods to treat hyperthyroidism patients, maintaining the moderate or high dose of methimazole without decreasing, such as adding levothyroxine to treat hypothyroidism when hypothyroidism occurs, in order to suppress the immune state of Graves' disease patients. However, the research results have not found that it can reduce the recurrence rate of hyperthyroidism. Analyzing the results of these clinical studies, it is found that the use time of methimazole in some studies of blocking replacement therapy is short, and the total treatment time is only one year, and all antibodies are not required to turn negative at the end of treatment. Some studies only focus on the negative conversion of TRAb antibody, but not on the negative conversion of other antibodies such as TgAb and TPOAb. Therefore, in this study, the intensive treatment group was treated with the inhibition substitution method of fixed middle dose methimazole plus levothyroxine, and the antibody was reduced after all turned negative, while the conventional treatment group was reduced according to whether the thyroid function was normal, so as to evaluate the effects of intensive treatment and conventional treatment on the cumulative recurrence of Graves' hyperthyroidism after two years of drug withdrawal. At the same time, the changes of immune indexes and inflammatory factors during the regulation process were evaluated. To provide evidence for improving the clinical remission rate of Graves' hyperthyroidism and exploring the etiology of Graves' hyperthyroidism.


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date July 31, 2030
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Graves hyperthyroidism (responsible for doctors' clinical diagnosis) - Age 18-65, for both men and women - Thyroid receptor antibody (TRAb) was positive - Take part in this research voluntarily and sign the informed consent form Exclusion Criteria: - Those who have used glucocorticoid or other immunosuppressants for a long time within 3 months before being selected - Those who have participated in any other drug trials within 3 months before being selected - Subjects who are participating in clinical research of other drugs - Patients with a history of malignant tumors - Ill-controlled hypertension: diastolic blood pressure=100mmHg, systolic blood pressure =160 mmHg - Blood routine: the total number of white blood cells < 3.0×109 or neutrophils < 1.5× 109 - Other thyroid diseases: such as subacute thyroiditis, thyroid nodules, high-function adenoma - Alanine aminotransferase(ALT) or aspartate amino transferase(AST) is greater than 2 times of the normal upper limit; When ALT or AST is less than 2 times of the normal upper limit, and the test of hepatitis B two half-and-half positive - Renal insufficiency: serum creatinine is higher than the upper limit of normal value - Patients with heart failure - Patients with coronary heart disease - Patients with other autoimmune diseases - Patients who are known to be allergic to any component of this medicine are allergic to the active ingredients or any auxiliary materials in the prescription - Patients with multiple drug allergies, allergic diseases, people with high sensitivity and drug addicts - Alcoholism, mental disorder or other observers who are not suitable for drug testing - Pregnant and lactating women cannot rule out the possibility of pregnancy - Taking any medicine with unknown ingredients or using traditional Chinese medicine, the researcher judges the medicine that may affect the curative effect of hyperthyroidism - According to the researcher's judgment, other medical history that reduces the possibility of joining the group or complicates the joining of the group, such as frequent changes in the working environment, may easily lead to lost follow-up. Rejection Criteria: - The compliance of this clinical trial protocol is < 80% or > 120%; - Those who did not meet the inclusion criteria or the exclusion criteria were found during the experiment; - Those who can't cooperate, including those who can't complete the whole course of treatment, don't complete the follow-up as planned, and increase or decrease adjuvant drugs at will; - During the trial, use other drugs that may affect the curative effect of this trial. Termination of Research Criteria: - Those who are allergic or intolerant to this drug; - Adverse reactions or serious adverse events that patients can't tolerate occur; - Pregnant women of childbearing age in the experiment; - Other diseases appear during the treatment, and the treatment of accompanying diseases will interfere with the clinical observers of this medicine; - The researcher thinks it is inappropriate to continue the experiment.

Study Design


Intervention

Drug:
Methimazole
Methimazole used in this study was produced by Merck, Germany, and its trade name is Thyrozol. The specification of this drug is 10mg/ tablet, and its validity period is 36 months. It was approved by FDA in 2009 and listed in China in 2011.

Locations

Country Name City State
China the First Affiliated Hospital of Nanjing Medical University Nanjing

Sponsors (1)

Lead Sponsor Collaborator
The First Affiliated Hospital with Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative recurrence rate between conventional treatment group and intensive treatment group after two years of withdrawal. Patients took medicine according to the course of treatment. Relapse occurs when the thyroid function returns to hyperthyroidism within 2 years after the drug is stopped. Up to 2 years after drug withdrawal
Primary Number of patients with no adverse reactions during the treatment of Graves' disease The patient completed the methimazole treatment, and there were no adverse reactions that needed to be stopped. Adverse reactions refer to any symptoms, syndromes or diseases that affect patients' health during clinical research and observation, and also include clinically relevant situations found in the laboratory or other diagnostic processes, such as unplanned diagnosis and treatment measures, withdrawal from research, or clinically significant laboratory examination items. Blood routine, liver function, kidney function and adverse reactions will be recorded during the follow-up. Within the treatment period (average 2 years)
Secondary Cumulative recurrence rate of hyperthyroidism in conventional treatment group and intensive treatment group after stopping treatment for one year. Patients took medicine according to the course of treatment. Relapse occurs when the thyroid function returns to hyperthyroidism within 1 years after the drug is stopped. Up to 1 years after drug withdrawal
Secondary Effects of routine treatment and intensive treatment on titer and positive rate of thyroid autoantibodies Thyroid function and related antibodies were detected every 4 ~ 8 weeks, and the positive rate and titers of thyroid autoantibodies (including TPOAb, TGAb and TRAb) were compared. During treatment(average 2 years) and within 2 years after drug withdrawal
Secondary Effect of conventional therapy and intensive therapy on thyroid volume The changes of thyroid volume during treatment and withdrawal were compared. During treatment(average 2 years) and within 2 years after drug withdrawal
Secondary Effects of conventional therapy and intensive therapy on cytokines The changes of cytokines before and after different treatments were compared. During treatment(average 2 years) and within 2 years after drug withdrawal
See also
  Status Clinical Trial Phase
Recruiting NCT05243134 - The Influence of Anatomic Deformities on the Clinical Efficacy in the Patients With Patellar Dislocation
Completed NCT02486874 - Clinical Evaluation of PoreSkin Phase 1
Active, not recruiting NCT04592640 - Stem Cells for Uremic Calciphylaxis Patients N/A
Recruiting NCT04599686 - Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer N/A
Recruiting NCT03351842 - Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20% Phase 2
Completed NCT03439930 - The Effect of Balance Training on Neuromuscular Control in Subjects With CAI N/A
Completed NCT02782442 - Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM) N/A
Not yet recruiting NCT05537155 - Buccal Acupuncture for Delirium Treatment in Older Patients Recovering From Orthopedic Surgery N/A
Recruiting NCT02971982 - PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia Phase 1/Phase 2
Completed NCT02820272 - Water for Reducing Pain in Negative Pressure Wound Therapy Phase 2
Completed NCT00984958 - Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure N/A
Completed NCT00575224 - Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9 Phase 4
Completed NCT00164307 - Assisting Children With Prenatal Alcohol Exposure in Developing Peer Friendships Phase 1/Phase 2
Completed NCT00164528 - Intervening With Children/Adolescents With FAS/ARND Phase 1/Phase 2
Recruiting NCT04603586 - Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses N/A
Recruiting NCT03375424 - Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany N/A
Not yet recruiting NCT04062370 - Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion Phase 4
Not yet recruiting NCT02931136 - Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging Phase 4
Completed NCT04661228 - Diagnostic Survey of Mental and Substance Use Disorders in HUNT (PsykHUNT)
Recruiting NCT03365141 - Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo N/A